CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
gadofosvesetdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01431300
NCT01431300N/ACompleted
CompareCT.gov

Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants

Duke University·interventional·Posted Sep 9, 2011·Updated Dec 10, 2013

In Brief

A clinical study evaluating gadofosveset for Healthy. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed while maintaining image quality. This will be a prospective randomized study, in which healthy volunteers will be recruited to undergo a central veins magnetic resonance angiogram (MRA). They will receive either the FDA-approved dose or a lower dose of Ablavar. Quantitative and qualitative analysis will be performed on the images.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsLantheus Medical Imaging

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 9, 2011
Enrollment StartAug 1, 2011
Primary CompletionJul 1, 2012
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.8 years ago

Interventions

gadofosvesetdrug

Intravenous administration of the specified dosage of gadolinium contrast agent